Immunome Inc. (IMNM): Price and Financial Metrics

Immunome Inc. (IMNM): $20.58

0.44 (-2.09%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add IMNM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#210 of 360

in industry

IMNM Price/Volume Stats

Current price $20.58 52-week high $30.96
Prev. close $21.02 52-week low $4.44
Day low $20.31 Volume 305,300
Day high $21.03 Avg. volume 690,362
50-day MA $23.01 Dividend yield N/A
200-day MA $12.27 Market Cap 1.23B

IMNM Stock Price Chart Interactive Chart >


Immunome Inc. (IMNM) Company Bio


Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.


IMNM Latest News Stream


Event/Time News Detail
Loading, please wait...

IMNM Latest Social Stream


Loading social stream, please wait...

View Full IMNM Social Stream

Latest IMNM News From Around the Web

Below are the latest news stories about IMMUNOME INC that investors may wish to consider to help them evaluate IMNM as an investment opportunity.

Immunome to Present at the Stifel 2023 Healthcare Conference

SEATTLE & EXTON, Pa., November 10, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Yahoo | November 10, 2023

Immunome Reports Third Quarter 2023 Financial Results

SEATTLE & EXTON, Pa., November 09, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Yahoo | November 9, 2023

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

SEATTLE & EXTON, Pa., November 08, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques "JJ" Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.

Yahoo | November 8, 2023

7 Biotech Stocks to Get In Now Before Investors Catch On

Biotech stocks are down, but there are hidden gems among the rubble.

John Blankenhorn on InvestorPlace | October 23, 2023

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

SEATTLE & EXTON, Pa., October 19, 2023--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic and industry executive in medical oncology and cancer research.

Yahoo | October 19, 2023

Read More 'IMNM' Stories Here

IMNM Price Returns

1-mo -8.29%
3-mo 56.38%
6-mo 130.72%
1-year 326.97%
3-year -26.05%
5-year N/A
YTD 92.34%
2023 384.16%
2022 -82.95%
2021 33.88%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!